Clinical trials
Squamous Cell Carcinoma clinical trials
Below are recruiting squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 879 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06408584Recruiting
Short radiation plus two drugs for returning esophageal cancer
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
HefeiAges 18 years+ - NCT06410651RecruitingPhase 2
Nimotuzumab with chemoradiation for advanced esophageal cancer
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
BeijingAges 18–80 - NCT06413342RecruitingPhase 2
Sintilimab after chemoradiation for older adults with esophageal cancer
This trial tests whether the immunotherapy drug Sintilimab can help prevent esophageal cancer from returning after standard chemotherapy and radiation. It is for patients aged 70-85 who cannot have or choose not to have surgery.
Hangzhou, ZhejiangAges 70–85 - NCT06476964Recruiting
Studying skin growths to better tell them apart
This study looks at different types of skin growths (actinic keratosis or cSCC) to understand their unique features. It may help doctors better tell apart harmless from dangerous skin spots by studying cells and inflammation.
BordeauxAges 18 years+ - NCT06479070Recruiting
Using ctDNA to guide radiotherapy for head and neck cancer
This study looks at whether measuring a DNA fragment in the blood (called ctDNA) can help predict how well radiotherapy works for head and neck cancer. It may help doctors better tailor treatment for patients with stage III or IV disease.
Caen, CaenAges 18 years+ - NCT06487403Recruiting
Delaying radiation for head and neck cancer: MRI and immune markers study
This study tests whether delaying radiation therapy can help doctors learn more from MRI scans and immune system changes in patients with head and neck cancer. This could lead to better treatment decisions.
Toronto, OntarioAges 18 years+ - NCT06494995RecruitingPhase 2
AK104 and low-dose radiation for advanced head and neck cancer
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06494943RecruitingPhase 1/Phase 2
Study of IBI110 and Sintilimab with Chemo for Head and Neck Cancer
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06510660RecruitingPhase 2
Immunotherapy and Chemoradiation for Advanced Esophageal Cancer
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Fuzhou, FujianAges 18–70 - NCT06525220RecruitingPhase 3
New drug combo vs. standard for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
Mobile, AlabamaAges 18 years+ - NCT06561178Recruiting
Blood Test to Monitor Esophageal Cancer After Surgery
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
Guangzhou, GuangdongAges Any age - NCT06589609RecruitingPhase 1
FluBHPVE6E7 immunotherapy for HPV16-positive oropharyngeal cancer
This trial tests a new immunotherapy called FluBHPVE6E7 for people with HPV16-positive oropharyngeal cancer that has not spread to distant parts of the body. The treatment is given directly into the tumor to help the immune system fight the cancer.
ViennaAges 18–65 - NCT06597565RecruitingPhase 2
ACR-368 plus low-dose gemcitabine for advanced head and neck cancer
This study tests a new combination of two drugs, ACR-368 and low-dose gemcitabine, for people with head and neck cancer that has come back or spread. The goal is to see if this treatment can help when immunotherapy or other therapies haven't worked.
Tampa, FloridaAges 18 years+ - NCT07567235RecruitingPhase 1
CFH Protein Ice Microneedles for Radiation Skin Damage
This study tests a new treatment using ice microneedles to deliver a healing protein (CFH) to prevent skin scarring and fibrosis after radiation therapy for head and neck cancer. The goal is to reduce long-term skin damage from cancer treatment.
Chengdu, SichuanAges 18–75 - NCT06601309RecruitingPhase 2
Study of treatments before surgery for esophageal cancer
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Fuzhou, FujianAges 18–75 - NCT06602843Recruiting
Chemoimmunotherapy before and after surgery for esophageal cancer
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
HefeiAges 18–75 - NCT06603402RecruitingPhase 2
Low-dose radiation plus immunotherapy for esophageal cancer
This trial tests a combination of low-dose radiation and immunotherapy for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective after initial treatment.
Chengdu, SichuanAges 18–80 - NCT06607406Recruiting
Timing of radiation after surgery for head and neck cancer
This study tests whether starting radiation therapy more than 6 weeks (but within 16 weeks) after surgery is safe and effective for people with certain high-risk head and neck cancers. It could help those who had to delay radiation for recovery or other reasons.
Charlotte, North CarolinaAges 18 years+ - NCT06611137RecruitingPhase 2
SBRT plus chemoimmunotherapy to save the voice box
This trial tests a new approach to treat advanced larynx or hypopharynx cancer without removing the voice box. First, you get targeted radiation (SBRT), then a combination of chemotherapy and an immunotherapy drug called Toripalimab, which helps your immune system fight the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06637163RecruitingPhase 2
Study of benmelstobart plus chemo-radiation before surgery for esophageal cancer
This trial tests whether adding an immunotherapy drug (benmelstobart) to standard chemotherapy and radiation before surgery can help treat a certain type of esophageal cancer that can be surgically removed. The goal is to see if this combination is safe and works better than standard treatment alone.
Shantou, GuangdongAges 18 years+ - NCT06642324Recruiting
HPV and genetics in head and neck cancer study
This study looks at how HPV infection and genetic changes relate to head and neck squamous cell carcinoma. If you have this type of cancer, joining could help doctors learn more about the disease and improve future treatments.
Dhaka, Dhaka DivisionAges 18 years+ - NCT06646588RecruitingPhase 2
Study of fruquintinib, tislelizumab, and radiation for esophageal cancer
This trial tests a combination of two drugs (fruquintinib and tislelizumab) followed by radiation therapy for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach can help shrink tumors and improve outcomes.
Shijiazhuang, HebeiAges 18 years+ - NCT06662929Recruiting
Arabic quality of life measure for head and neck cancer patients
This study will test a new Arabic questionnaire to measure how radiotherapy affects the quality of life of head and neck cancer patients. If you are receiving, have received, or will receive radiation treatment for head or neck cancer, you may be able to help by filling out surveys.
RiyadhAges 18 years+ - NCT06669572RecruitingPhase 2
Lenvatinib and pembrolizumab for advanced anal or rectal cancer
This trial tests a combination of two drugs, lenvatinib and pembrolizumab, for people with anal or rectal cancer that has spread or cannot be removed and has worsened after initial treatment. The goal is to see if this combination can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for squamous cell carcinoma?
- Yes. Clin2 currently lists 879 recruiting squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.